BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustide M, Maticic M, Harris M, Metwally AM, Razavi H, Lazarus JV; Hep-CORE Study Group. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS One 2020;15:e0235715. [PMID: 32722701 DOI: 10.1371/journal.pone.0235715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861 [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852] [Reference Citation Analysis]
3 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
4 Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017;22:E191. [PMID: 28125040 DOI: 10.3390/molecules22020191] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 26.4] [Reference Citation Analysis]
5 Mandoh SS, Ayman K, Elbardakheny A, Raaft H, Ibrahim AA, Alshaikh RA, Mansour FR. A cross sectional study of the risk factors of hepatitis C infection in North Egypt. Virusdisease 2021;32:22-8. [PMID: 33969153 DOI: 10.1007/s13337-020-00639-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pena DZ, Anadão MF, Flores EF, Okada MN, Filho AMP, Ferro RS, Prestes-Carneiro LE. Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil. Microorganisms 2020;8:E1575. [PMID: 33066136 DOI: 10.3390/microorganisms8101575] [Reference Citation Analysis]
7 Ali M, Khan T, Fatima K, Ali QUA, Ovais M, Khalil AT, Ullah I, Raza A, Shinwari ZK, Idrees M. Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions. Phytother Res 2018;32:199-215. [PMID: 29047177 DOI: 10.1002/ptr.5957] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
8 Malsagova KA, Pleshakova TO, Galiullin RA, Kaysheva AL, Shumov ID, Ilnitskii MA, Popov VP, Glukhov AV, Archakov AI, Ivanov YD. Ultrasensitive nanowire-based detection of HCVcoreAg in the serum using a microwave generator. Anal Methods 2018;10:2740-9. [DOI: 10.1039/c8ay00495a] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wahid B, Naeem N, Altaf S, Ilyas N. Increasing Prevalence of Untypable and Mixed Genotypes of Hepatitis C Virus in Pakistan: Latest Trends in 2018. Viral Immunol 2019;32:192-4. [PMID: 30939104 DOI: 10.1089/vim.2018.0152] [Reference Citation Analysis]
10 Almas I, Afzal S, Idrees M, Ashraf MU, Amin I, Shahid M, Zahid K, Zahid S. Role of circulatory microRNAs in the pathogenesis of hepatitis C virus. Virusdisease. 2017;28:360-367. [PMID: 29291226 DOI: 10.1007/s13337-017-0407-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Ortega-Prieto AM, Dorner M. Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel). 2017;5:pii: E24. [PMID: 28862649 DOI: 10.3390/vaccines5030024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
12 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
13 Chikovani I, Ompad DC, Uchaneishvili M, Sulaberidze L, Sikharulidze K, Hagan H, Van Devanter NL. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. PLoS One 2019;14:e0216123. [PMID: 31034530 DOI: 10.1371/journal.pone.0216123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
14 Li XM, Qiu RX, Song CH, Huang QH, Wang XD, Hu ZT, He XZ, Ye XY, Huang XG, Zheng FF, Lin GX. Genotype and genetic variation of HCV infections with low-risk factors in Putian coastal regions, China. Epidemiol Infect 2017;145:3385-97. [PMID: 29081304 DOI: 10.1017/S0950268817002357] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Brady Z, Stoykova Z. Hepatitis C virus genotype analysis in patients with chronic hepatitis in North Eastern Bulgaria. J Drug Assess. 2019;8:146-149. [PMID: 31552145 DOI: 10.1080/21556660.2019.1654484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Chang SW, Cheng ML, Shiao MS, Yeh CT, Wang CH, Fan CM, Chiu CT, Chang ML. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation. J Clin Lipidol 2018;12:756-66. [PMID: 29574072 DOI: 10.1016/j.jacl.2018.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
18 Bulut ME, Topalca US, Murat A, Teke L, Canalp HZ, Ocal M, Bayraktar B. HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul. Sisli Etfal Hastan Tip Bul 2021;55:86-92. [PMID: 33935541 DOI: 10.14744/SEMB.2020.66990] [Reference Citation Analysis]
19 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
20 Iossa D, Vitrone M, Gagliardi M, Falco E, Ragone E, Zampino R, Durante-Mangoni E. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. Ann Transl Med 2021;9:35. [PMID: 33553328 DOI: 10.21037/atm-20-669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
22 Fu N, Du H, Li D, Lu Y, Li W, Wang Y, Kong L, Du J, Zhao S, Ren W, Han F, Wang R, Zhang Y, Nan Y. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy. Life Sciences 2020;256:117911. [DOI: 10.1016/j.lfs.2020.117911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tewari D, Mocan A, Parvanov ED, Sah AN, Nabavi SM, Huminiecki L, Ma ZF, Lee YY, Horbańczuk JO, Atanasov AG. Ethnopharmacological Approaches for Therapy of Jaundice: Part I. Front Pharmacol 2017;8:518. [PMID: 28860989 DOI: 10.3389/fphar.2017.00518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Isakov V, Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective. Viruses 2022;14:790. [DOI: 10.3390/v14040790] [Reference Citation Analysis]
25 Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L. Epidemiology, patient profile, and health care resource use for hepatitis C in Italy. Clinicoecon Outcomes Res 2017;9:609-16. [PMID: 29066922 DOI: 10.2147/CEOR.S136456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
26 Petruzziello A, Marigliano S, Loquercio G, Coppola N, Piccirillo M, Leongito M, Azzaro R, Izzo F, Botti G. Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. Infect Agents Cancer 2017;12. [DOI: 10.1186/s13027-017-0162-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
27 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Taconet L, Seifner A, Baylis SA, Chudy M, Kreβ J, Mathys E, Wirz M, Buchheit KH, Behr-Gross ME. Detection of hepatitis C virus and parvovirus B19 in human plasma pools by nucleic-acid amplification techniques - Trends in results of EDQM proficiency testing studies from 2004 to 2018. Biologicals 2021;71:9-19. [PMID: 34006447 DOI: 10.1016/j.biologicals.2021.04.004] [Reference Citation Analysis]
30 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
31 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
32 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
33 Kracht PAM, Arends JE, van Erpecum KJ, Urbanus A, Willemse JA, Hoepelman AIM, Croes EA. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy. 2018;3:12. [PMID: 30288334 DOI: 10.1186/s41124-018-0040-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
34 Kurtenkov O, Jakovleva J, Sergejev B, Geller J. Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy. Dis Markers 2020;2020:8881279. [PMID: 32685058 DOI: 10.1155/2020/8881279] [Reference Citation Analysis]
35 Passerini M, Schiavini M, Magni CF, Landonio S, Niero F, Passerini S, Croci AL, Bolis M, Scalzi V, Gubertini G, Ricci ED, Galli M, Rizzardini G. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. Eur J Gastroenterol Hepatol 2018;30:1208-15. [PMID: 30138160 DOI: 10.1097/MEG.0000000000001239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
36 Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group. Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect 2018;24:422-7. [PMID: 28765078 DOI: 10.1016/j.cmi.2017.07.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
37 Pereira FM, Almeida MDCC, Santos FLN, Carreiro RP, Galvão-Castro B, Grassi MFR. Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil. PLoS One 2020;15:e0223087. [PMID: 32692782 DOI: 10.1371/journal.pone.0223087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Isakov V, Tsyrkunov V, Nikityuk D. Is elimination of hepatitis C virus realistic by 2030: Eastern Europe. Liver Int 2021;41 Suppl 1:50-5. [PMID: 34155800 DOI: 10.1111/liv.14836] [Reference Citation Analysis]
39 Sikander M, Malik S, Rodriguez A, Yallapu MM, Narula AS, Satapathy SK, Dhevan V, Chauhan SC, Jaggi M. Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction. Molecules 2020;25:E5905. [PMID: 33322162 DOI: 10.3390/molecules25245905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, Cicchetti A. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert Rev Pharmacoecon Outcomes Res 2019;19:363-74. [PMID: 30351994 DOI: 10.1080/14737167.2019.1537784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 [DOI: 10.1101/19004960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Xiang Y, Lai XF, Chen P, Yang Y. The correlation of HCV RNA and HCV core antigen in different genotypes of HCV. J Clin Lab Anal 2019;33:e22632. [PMID: 30069909 DOI: 10.1002/jcla.22632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]